logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Key Capital cORP. (KCPC.OB)
COVID-19 oral pill vaccine
Laboratory testing

On Jan.18, 2021, the company announced promising safety profile and 90% reduction in virus infectivity in mammalian cells
-
-
01/20/2021
Johnson & Johnson
(JNJ)
Ad26.COV2.S Vaccine
Phase 3 trial of a two-dose regimen of Ad26.COV2.S, dubbed ENSEMBLE 2
-
UK National Institute for Health Research (NIHR)
12/31/2020
CohBar, Inc.
(CWBR)
CB5064
Preclinical model of Acute Respiratory Distress Syndrome treated with CB5064 generated positive results
-
-
12/30/2020
CureVac N.V.
(CVAC)
CVnCoV
-- Phase IIa clinical trial in Peru and Panama initiated in Sep.2020
-- Pivotal Phase 2b/3 study of CVnCoV initiated on Dec.14, 2020 in Europe and Latin America
-- phase 3 trial initiated on Dec.21, 2020 at the University Hospital Mainz
-
CEPI, Bill & Melinda Gates Foundation and Defense Advanced Research Projects Agency (DARPA)
12/30/2020
Atea Pharmaceuticals, Inc.
(AVIR)
AT-527
Phase 2 trial of AT-527 for patients hospitalized with moderate COVID-19
-
-
12/29/2020
Aerpio Pharmaceuticals, Inc.
(ARPO)
Razuprotafib for the treatment of acute respiratory distress syndrome in adult patients w
phase 2 study (I-SPY COVID Trial)
Data in 1H, 2021
Quantum Leap Healthcare Collaborative
12/29/2020
Akari Therapeutics Plc
(AKTX)
Nomacopan for COVID-19 pneumonia patients
Phase I/II study in the U.K. to determine the safety and effectiveness of multiple drugs for the treatment of COVID-19 (AGILE)
-- Initial review of UK study expected early 2021.
-- Initiation of a randomized multi-center randomized study in patients hospitalized with COVID-19 pneumonia in the U.S. planned for Q1, 2021
-
12/28/2020
Agenus Inc.
( AGEN, AGEND)
iNKT Cell Therapy
First COVID-19 patient dosed with iNKT cell therapy on Nov.2, 2020
-
-
12/28/2020

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Intel Corp. said it is probing into the hack of its fourth-quarter earnings report that prompted the chipmaker to release its earnings statement ahead of schedule. The company, which was scheduled to release the results after the market closed, released it before the market closing on Thursday. Google parent Alphabet decided to drop its Internet balloon project Loon that was launched with the idea of providing Internet access to rural areas and providing last mile connectivity. In a blog post, Loon CEO Alastair Westgarth said they have not found a way to get the costs low enough to build a long-term, sustainable business, despite gaining a number of interested partners along the way. American Airlines announced the launch of Flagship Cellars, its home delivery service for premium wines usually available onboard. The airline's move is said to be due to the excess wine it has amid the weakness in air travel demand following the coronavirus pandemic crisis. The company expects the new at-home wine program to generate about $40,000 to $50,000 in sales during the first quarter.